Moleculin Posts Encouraging Phase 2/3 MIRACLE Trial Results; Shares Down Despite Data

Moleculin Biotech reported positive interim efficacy results from Part A of its pivotal Phase 2/3 MIRACLE trial of annamycin in relapsed/refractory acute myeloid leukemia, based on data from the first 45 enrolled patients. While the release is efficacy-supportive, the absence of detailed outcome metrics in the excerpt limits certainty around magnitude and durability.

Analysis

Moleculin Biotech reported positive interim efficacy results from Part A of its pivotal Phase 2/3 MIRACLE trial of annamycin in relapsed/refractory acute myeloid leukemia, based on data from the first 45 enrolled patients. While the release is efficacy-supportive, the absence of detailed outcome metrics in the excerpt limits certainty around magnitude and durability.